Αρχική World News New on NCI’s Websites for January 2020

New on NCI’s Websites for January 2020

, by NCI Staff

Available cancer prevention interventions include medications, lifestyle choices, treatments for infections, screening tests, protective vaccines, and surgery.

NCI’s collection of cancer information products is constantly growing, so we provide periodic updates on new and updated content of interest to the cancer community.

New Blog: Cancer Prevention Science

NCI’s Division of Cancer Prevention (DCP) recently debuted its new blog. Cancer Prevention Science highlights recent research findings, features interviews with leaders in the fields of cancer prevention and supportive care, and introduces new projects and programs supported by DCP.

Immunotherapy Drug Improves Outcomes for Some Children with Relapsed Leukemia

New findings from an NCI-sponsored clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed.

Expanded Information about Immunotherapy

NCI has made a number of updates to its information about immunotherapy treatment for people with cancer. The section now includes pages about different types of immunotherapy and side effects these treatments may cause.

New Issue of DCTD Pipeline News Posted

The November 2019 issue of Pipeline News, a quarterly newsletter from the Division of Cancer Treatment and Diagnosis (DCTD), includes a profile of Bhadrasain Vikram, M.D., chief of the Radiation Research Program’s Clinical Radiation Oncology Branch; a spotlight on results of a clinical trial of the drug selumetinib; updates from the NCI Experimental Therapeutics (NExT) Program; and news about other DCTD programs and activities.

NCI to Support Cell Therapy Production for Multicenter Clinical Trials

DCTD has announced it will soon support the production of cell-based immunotherapies at NCI, allowing NCI to make cell therapy products, such as CAR T cells, available to intramural and extramural clinical trial investigators.

New Issue of OCG e-Newsletter Published

The Office of Cancer Genomics (OCG) has published issue 23 of the OCG e-Newsletter. Topics include: crowd-sourcing DREAM challenges, in collaboration with the Cancer Target Discovery and Development (CTD2) Network, to develop predictive algorithms to identify effective cancer treatments; databases and other resources available for community use; a perspective on cancer genomics research; and clinical molecular data of Human Cancer Models Initiative (HCMI) next-generation cancer models that can be accessed through NCI’s Genomic Data Commons (GDC).

New Websites for CCR Multidisciplinary Clinics

NCI’s Center for Cancer Research (CCR) has launched new websites for its Prostate Cancer Multidisciplinary Clinic and Medullary Thyroid Carcinoma Clinic. The prostate cancer clinic provides comprehensive consultations on diagnosis and treatment options to prostate cancer patients. The thyroid clinic includes a multidisciplinary team that reviews cases of individuals affected by medullary thyroid carcinoma for treatment and management of their disease.

Video Describes Trial for Patients with Gastrointestinal Tumors

Jonathan Hernandez, M.D., a clinical investigator in CCR’s Surgical Oncology Program, and his research team are dedicated to improving cancer treatment by developing novel human tissue models. In a new video, Dr. Hernandez describes his team’s latest clinical trial for patients with operable gastrointestinal tumors.

New Video: Discovering New Far-Red Fluorescent Probes

CCR has created a new video to help explain the discovery of a novel class of molecules used by biologists to illuminate the inner workings of cancer cells: far-red fluorescent probes. Researchers in the lab of Martin Schnermann, Ph.D., used synthetic chemistry to synthesize the probes, which may make it possible to image live tissue in greater depth and detail than is possible with current techniques.



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

Radiation Treatment Delivery Improved Using a Visualization of the Invisible Radiation Beam

When a cancer patient is undergoing radiation treatment, neither she nor the radiation therapist providing the treatment can see the actual beam of radiation....

Los obstáculos en la atención para las personas LGBTQ con cáncer: perspectiva de un experto

Matthew Schabath, PhD, es epidemiólogo del cáncer en el Moffitt Cancer Center de Tampa, Florida. El Dr. Schabath ha estado trabajando en investigación sobre...

Understanding FDA Emergency Use Authorization

In the United States, before any vaccine can be given, it must be approved by the FDA (Food and Drug Administration). This process usually...

Risk Tool Predicts Severe Chemotherapy Toxicity in Elderly Patients with Early Breast Cancer

Allison Magnuson of the University of Rochester in Rochester, NY, US and colleagues reported on 14 January 2021 in the Journal of Clinical Oncology...

Begin Each Day…

Our goal should be to live life in radical amazement. ….get up in the morning and look at the world in a way that...

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for HER2-positive Gastric Adenocarcinomas

On 15 January 2021, the US Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or...